Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Apyx Medical CorporationNASDAQ: APYX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $202K rose 46.4% year over year, ahead of the +18.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -9.7% a year.

Context

  • Depreciation & amortization amounted to 1.2% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +46.4% holds above the trailing-twelve-month pace of +18.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$202K-8.6% QoQ
Last fiscal yearDec 2025
$655K+9.3% YoY
LTMMar 2026
$687K+18.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.4%——
1 year+9.3%——
3-year CAGR-9.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
655K USD
Year-over-year change
+9.3%
4-year CAGR
-7.7%

Depreciation & Amortization vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 depreciation & amortization of $687K is the 7th highest of the 8 companies compared; the peer median is $2.28M.
  • Its year-over-year change of +18.4% is the 3rd highest of 8, against a peer median of +9.7%.
  • Depreciation & amortization amounts to 1.2% of revenue for APYX, versus a peer median of 6.4%.
APYX Competitors Peer median
Depreciation & Amortization for APYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$4.68M +9.1%+59.1%3.8%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$3.11M -4.9%+4.7%9.0%
RCELAVITA Medical, Inc.LTM Mar 2026$2.45M +69.9%+60.5%3.4%
PDEXPro-Dex, Inc.LTM Mar 2026$2.28M +85.2%+19.5%3.1%
SERASera Prognostics, Inc.LTM Mar 2026$917K +9.7%+7.5%1608.8%
LUCDLucid Diagnostics Inc.LTM Mar 2026$873K -1.6%-23.3%17.0%
APYXApyx Medical CorporationLTM Mar 2026$687K +18.4%-9.7%1.2%
VANIVivani Medical, Inc.LTM Mar 2026$452K +12.2%+3.6%—
Peer median (excluding APYX) $2.28M+9.7%+7.5%6.4%

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.52M44.51M52.35M48.1M52.84M
Cost of Revenue14.92M15.38M18.59M18.74M33.81M
Gross Profit33.6M29.13M33.76M29.36M19.03M
Gross Margin69.3%65.4%64.5%61.0%36.0%
Research & Development4.32M4.54M4.84M5.08M3.37M
Selling, General & Admin43.73M48.15M48.87M43.13M36.12M
Operating Expenses48.05M52.69M51.02M48.21M25.48M
Depreciation & Amortization903K890K692K599K655K
EBITDA(13.91M)(22.01M)(18.11M)(16.8M)(4.59M)
EBITDA Margin-28.7%-49.4%-34.6%-34.9%-8.7%
Operating Income(14.45M)(23.56M)(17.26M)(18.85M)(6.45M)
Operating Margin-29.8%-52.9%-33.0%-39.2%-12.2%
Interest Income11K157K921K1.61M1.11M
Interest Expense10K15K2.48M5.91M5.59M
Other Income / Expenses(372K)651K(4.02M)(4.46M)(4.39M)
Income Before Tax(14.82M)(22.91M)(21.28M)(23.31M)(10.84M)
Pre-Tax Margin-30.5%-51.5%-40.7%-48.5%-20.5%
Income Tax Expense380K367K(2.43M)252K270K
Net Income(15.17M)(23.18M)(18.71M)(23.46M)(11.21M)
Net Margin-31.3%-52.1%-35.7%-48.8%-21.2%
EPS (Basic)(0.44)(0.67)(0.54)(0.66)(0.27)
EPS (Diluted)(0.44)(0.67)(0.54)(0.66)(0.27)
Weighted Avg Shares34.33M34.52M34.62M35.54M42.16M
Weighted Avg Shares (Diluted)34.33M34.52M34.62M35.54M42.16M

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.